Keywords: remicade, gains, fda, priority, cd, centocor, infliximab

Remicade gains FDA priority for CD

Article | 08 April 2002

Print This

Centocor's Remicade (infliximab) has been designated for priority reviewby the US Food and Drug Administration as a monotherapy for inducing ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in